Cell Membrane Fusion Proteins Enhance AAV Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy using adeno-associated virus (AAV) vectors faces challenges with limited transduction efficacy and high vector dose requirements, leading to immune responses and inefficient transgene expression, particularly in clinical settings.
Innovation Solution
The use of cell membrane fusion proteins, specifically the FerA domain fragments, to enhance the introduction of heterologous agents, such as AAV vectors, into host cells by forming complexes that improve transduction efficiency and reduce vector dose requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high vector dose is used to improve transduction efficacy, then transduction efficiency increases, but immune responses are activated and transduction efficiency is hindered
Solution Approach 1:
The patent uses cell membrane fusion proteins as intermediary substances that facilitate AAV vector entry into host cells. These proteins act as mediators between the AAV vector and the cell membrane, enabling efficient transduction at lower vector doses without triggering immune responses. The fusion proteins form complexes with AAV vectors and promote their internalization into target cells, resolving the contradiction between achieving high transduction efficiency and avoiding immune activation.
Solution Approach 2:
The patent changes the physical and chemical parameters of the delivery system by incorporating cell membrane fusion proteins that alter the interaction between AAV vectors and cell membranes. This parameter change enables the system to achieve high transduction efficiency at lower vector doses, thereby avoiding the activation of cellular immune responses that occur with high-dose vector administration.
2Object-affected harmful factors
If vector dose is decreased to reduce immune responses, then immune activation is reduced, but transduction efficacy becomes limited
Solution Approach 1:
Cell membrane fusion proteins serve as intermediary agents that enhance the transduction capability of AAV vectors at low doses. These proteins bind to AAV vectors and facilitate their entry into host cells through membrane fusion mechanisms, thereby maintaining high transduction efficacy even when vector dose is reduced to minimize immune responses.
Solution Approach 2:
The patent creates a composite delivery system by combining AAV vectors with cell membrane fusion proteins. This composite material exhibits enhanced transduction properties that allow effective gene delivery at lower vector concentrations, thus reducing immune activation while maintaining high transduction efficacy.
3Productivity
If AAV capsid is modified to improve transduction, then transduction efficiency may increase, but structural and tropism changes become unpredictable
Solution Approach 1:
Instead of modifying the AAV capsid structure, the patent introduces cell membrane fusion proteins as external intermediaries that facilitate viral entry. This approach maintains the natural structure and tropism of the AAV capsid while achieving enhanced transduction efficiency, thereby avoiding unpredictable changes in structural properties and tissue tropism.
4Adaptability or versatility
If targeting ligands are covalently coupled to AAV particles to achieve selective gene transfer, then cell type specificity improves, but device complexity increases
Solution Approach 1:
The patent uses cell membrane fusion proteins as intermediaries that naturally interact with specific cell types through their inherent membrane fusion properties. This approach achieves cell type selectivity without requiring complex covalent coupling of targeting ligands to the AAV capsid, thereby maintaining simpler vector construction while achieving selective gene transfer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly increases AAV transduction efficiency across various tissues and species, achieving consistent transgene expression with lower vector doses and minimizing immune responses.
Implementation Method 1
contacting the host cell with the heterologous agent in the presence of a cell membrane fusion protein or a functional fragment or derivative thereof
Data Source
AI summary
The invention relates to methods and compositions for increasing introduction (e.g., transduction) efficiency. In particular, the invention relates to methods of increasing introduction (e.g., transduction) efficiency by contacting a host cell with a heterologous agent in the presence of a cell membrane fusion protein or a functional fragment or derivative thereof. The invention further relates to compositions that include a heterologous agent and a cell membrane fusion protein or a functional fragment or derivative thereof.